Yuka Kudo-Nagata

Yuka Kudo-Nagata

Auto-generated profile, based on publicly available information

Yuka Kudo-Nagata

Department of Infection Prevention and Control, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2026 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KOKoji Ohyama
Koji Ohyama
AFAkiko Furusawa
Akiko Furusawa
YKYuka Kudo-Nagata
Yuka Kudo-Nagata
NKNao Kino
Nao Kino
NSNoritaka Sekiya
Noritaka Sekiya

9 September 2026 in medRxiv
Verified
Preprint
Open access
PDF file
YTYui Tomo
Yui Tomo
SJSeowoong Jung
Seowoong Jung
YKYuka Kudo-Nagata
Yuka Kudo-Nagata
RSRyoko Sekiya
Ryoko Sekiya
KFKazuaki Fukushima
Kazuaki Fukushima
AKAyu Kasamatsu
Ayu Kasamatsu
Background: Advances in antiretroviral therapy (ART) have transformed human immunodeficiency virus (HIV) infection into a manageable chronic condition. However, people with HIV (PWH) face an increased burden of age-related non-AIDS-defining illnesses. Epigenetic age (EA) and epigenetic age acceleration (EAA), based on DNA methylation, have emerged as objective indicators of biological aging. Although studies in Western countries suggest that EAA levels are elevated in PWH and may decline after ART initiation, evidence in the Japanese population remains scarce. This study aims to characterize EA and EAA in Japanese PWH and to evaluate their associations with the duration of ART, cumulative exposure to specific drug classes, frailty, lifestyle factors, and immunological, metabolic, and inflammatory markers. Methods: This single-center, cross-sectional study involves 100 adult Japanese males with HIV who have received ART for at least 12 months. EA and EAA will be calculated using whole-blood DNA methylation data generated using the Illumina Infinium MethylationEPIC v2.0 BeadChip array and epigenetic clocks developed on Japanese populations. Linear regression models will be used to evaluate the associations between EAA and the factors collected from medical records, laboratory tests, self-administered questionnaires, and comorbidities. Discussion: This study provides baseline data for future longitudinal and comparative studies. The integration of clinical, questionnaire, and omics data facilitates the exploration of biological mechanisms underlying aging in this population. The limitations include the cross-sectional design, which precludes causal inference and the lack of a control group. Graphical

6 June 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
YKYuka Kudo-Nagata
Yuka Kudo-Nagata
KFKazuaki Fukushima
Kazuaki Fukushima
TSTaro Sugimoto
Taro Sugimoto
TOTomotake Okuma
Tomotake Okuma
THTakahiro Hozumi
Takahiro Hozumi
AIAkifumi Imamura
Akifumi Imamura
Epstein-Barr virus–associated smooth-muscle tumor (EBV-SMT) is a rare tumor that occurs in immunosuppressed individuals. Among people living with human immunodeficiency virus (HIV), opportunistic infections are more likely to determine prognosis than EBV-SMT itself. Herein, we describe a patient with HIV whose airway became obstructed due to one of the multiple tumor nodules of EBV-SMT. This 36-year-old woman living with advanced HIV presented with sudden dyspnea. On presentation, she experienced respiratory failure due to airway obstruction, requiring an emergency tracheostomy. Examinations revealed multiple lesions in the right patella, 12th thoracic vertebra, and upper glottis, all diagnosed as EBV-SMT. Despite antiretroviral therapy, surgical interventions were required for disease control. She has remained recurrence free for >3 years after resection. Although EBV-SMT is generally considered an indolent tumor, this case demonstrates that it can cause life-threatening complications, for which a timely multidisciplinary team approach is most crucial.